News

Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, announced a clinical…
Read More...

The Phase 3 ENSEMBLE study of the single-dose regimen of JNJ-78436735, the investigational vaccine candidate for the prevention of COVID-19 being developed by the Janssen Pharmaceutical…
Read More...

Taiho Pharmaceutical Co., Ltd and Lung Therapeutics, Inc. announced an exclusive license agreement of LTI-01, a recombinant human single-chain urokinase plasminogen activator, currently…
Read More...

Jubilant Therapeutics Inc. a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, and OneThree Biotech, a…
Read More...

Pfizer and BioNTech SE announced that they have reached an agreement with the European Commission to supply 200 million doses of their investigational BNT162b2 mRNA-based vaccine…
Read More...

Brazil's National Health Surveillance Agency (Anvisa) authorizes resumption of the phase III clinical trial of CoronaVac™, the Inactivated COVID-19 Vaccine, which is sponsored by our…
Read More...

Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced that it has launched its Phase 2 CAMELOT trial to evaluate the safety and efficacy of Camostat Mesilate (Camostat) for the…
Read More...

Medigen Vaccine Biologics Corporation, a biopharmaceutical company focusing on the development and production of vaccines and biologics, and BlueWillow Biologics, Inc., a privately held…
Read More...

Xencor, MorphoSys AG and Incyte (NASDAQ: INCY) today announced a clinical collaboration to investigate the combination of tafasitamab, plamotamab and lenalidomide in patients with…
Read More...

Adagio Therapeutics, Inc., a company developing best-in-class antibodies that broadly neutralize SARS-CoV-2, SARS-CoV-1, and additional potentially emergent coronaviruses, announced the…
Read More...

Forma Therapeutics Holdings, Inc. announced the European Commission granted Orphan Drug designation to Forma’s FT-4202 for the treatment of sickle cell disease (SCD), based on a…
Read More...

ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. a clinical-stage, natural killer cell-based therapeutics company, announced they have administered their…
Read More...

Insilico Medicine, a leader in deep generative reinforcement learning for target discovery, small molecule generation, and prediction of clinical trial outcomes, announced that it…
Read More...

Sedor Pharmaceuticals, LLC (Sedor) announced that the U.S. Food and Drug Administration (FDA) has approved SESQUIENT (fosphenytoin sodium for injection) for the treatment of status…
Read More...

The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for Eli Lilly and Company's investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg.…
Read More...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, announced that an independent…
Read More...

Amgen and AstraZeneca announced positive topline results from the Phase 3 NAVIGATOR trial in which the investigational medicine tezepelumab demonstrated a statistically significant…
Read More...

AstraZeneca’s Calquence (acalabrutinib), a next-generation selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) for the treatment of adult…
Read More...

Vifor Pharma and Angion Biomedica Corp. (Angion) announced the signing of a licensing agreement for the commercialization of ANG-3777, currently being developed for treatment of delayed…
Read More...

Ultragenyx Pharmaceutical Inc. a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare genetic diseases, announced that it…
Read More...